RGNX — REGENXBIO Inc.

Summary of REGENXBIO Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, REGENXBIO reported cash, cash equivalents, and marketable securities of $241 million, down slightly from $245 million in 2024.
• Revenue: Total annual revenue for 2025 was $170 million, driven by a $110 million upfront payment from Nippon Shinyaku and increased royalty revenue from Zolgensma and Evrysdi.
• R&D Expenses: R&D expenses rose to $228 million in 2025 from $209 million in 2024, primarily due to costs associated with pivotal trial execution and manufacturing.
• Cash Runway: The current cash balance is expected to fund operations into early 2027, excluding potential milestones from AbbVie and future revenue from MPS programs.

2. Strategic Updates and Business Highlights

• Pipeline Advancements: REGENXBIO is focused on late-stage programs, particularly RGX-202 for Duchenne muscular dystrophy (DMD) and Cirovec for wet AMD and diabetic retinopathy (DR).
• RGX-202: Completed dosing in the pivotal study and reported strong enrollment in the confirmatory trial. The company anticipates topline data in Q2 2026 and plans to engage with the FDA regarding a BLA submission using the accelerated approval pathway.
• Cirovec: Topline data for wet AMD is expected in Q4 2026, with site activation for the NAVIGATE trial in DR underway, which could trigger a $100 million milestone from AbbVie.
• MPS Programs: The company is addressing clinical holds on RGX-111 and RGX-121 and is preparing for a Type A meeting with the FDA regarding the CRL received for RGX-121.

3. Forward Guidance and Outlook

• 2026 Expectations: The company is positioned for a transformative year with pivotal readouts and potential product launches in DMD, wet AMD, and DR.
• Regulatory Engagement: REGENXBIO plans to continue discussions with the FDA to align on data requirements for the BLA submission and to ensure clarity on the use of external control data in their analyses.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The company faces challenges with the FDA regarding the design of confirmatory studies and the acceptance of their data analysis methods, particularly in comparison to competitors like Sarepta and Elevidys.
• Clinical Holds: The clinical holds on MPS programs present a significant hurdle, and the company must address the issues raised in the CRL effectively to move forward.
• Safety Concerns: There are ongoing concerns in the industry regarding safety profiles of AAV therapies, particularly following setbacks from competitors, which could influence regulatory scrutiny and market perception.

5. Notable Q&A Insights

• DMD Data Confidence: Management expressed confidence in their data supporting accelerated approval, citing robust functional outcomes compared to natural history models.
• Safety Profile: REGENXBIO reported no cases of liver injury or thrombocytopenia in the RGX-202 study, which they believe differentiates them from competitors.
• Regulatory Strategy: There was discussion about the importance of FDA interactions leading up to the pre-BLA meeting, emphasizing the need for alignment on data analysis methods.
• Market Dynamics: The company acknowledged the growing prevalence of DMD and the urgent need for new therapies, positioning their products as critical solutions in the market.

Overall, REGENXBIO is navigating a pivotal phase with significant potential for growth, but faces challenges related to regulatory approvals and safety perceptions in the competitive landscape.